Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study

This media program reviews new clinical data from the SOHO-01 study evaluating sevabertinib, an oral HER2-targeted therapy, in patients with advanced HER2-mutant non-small cell lung cancer. Experts discuss the study design, patient population, and key efficacy and safety findings presented at the ESMO Congress. The discussion also explores how these results may influence future treatment strategies for patients with HER2-mutant NSCLC.